Detalhe da pesquisa
1.
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
Trials
; 24(1): 180, 2023 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906660